Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathon B Cohen

Showing results (81-90 of 129) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2022
Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaAndres Chang, Akil Akhtar, Susanne L Linderman, et al.
Blood Advances|August 30, 2024
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantationNarendranath Epperla, Ying Huang, Amanda F Cashen, et al.
Cancers|July 29, 2025
Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CARTNicole J Altomare, Megan M Herr, Nisha M Nair, et al.
Blood|September 10, 2024
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysisBrooj Abro, Matthew J Maurer, Thomas M Habermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2020
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and ToxicityCaron A Jacobson, Bradley D Hunter, Robert Redd, et al.
Journal of Hematology & Oncology|November 10, 2023
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Lei Feng, Nirav N Shah, et al.
Annals of Hematology|October 18, 2023
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphomaReid W Merryman, Robert A Redd, Arnold S Freedman, et al.
Cancer|July 28, 2017
C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapyNarendranath Epperla, Kami J Maddocks, Mohammed Salhab, et al.
American Journal of Hematology|November 24, 2016
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapiesLuciano J Costa, Kami Maddocks, Narendranath Epperla, et al.
Cancer Research Communications|January 16, 2023
Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignanciesAndres Chang, Akil Akhtar, Lilin Lai, et al.
Pageof 13

Showing results (81-90 of 129) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2022
Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaAndres Chang, Akil Akhtar, Susanne L Linderman, et al.
Blood Advances|August 30, 2024
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantationNarendranath Epperla, Ying Huang, Amanda F Cashen, et al.
Cancers|July 29, 2025
Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CARTNicole J Altomare, Megan M Herr, Nisha M Nair, et al.
Blood|September 10, 2024
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysisBrooj Abro, Matthew J Maurer, Thomas M Habermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2020
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and ToxicityCaron A Jacobson, Bradley D Hunter, Robert Redd, et al.
Journal of Hematology & Oncology|November 10, 2023
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Lei Feng, Nirav N Shah, et al.
Annals of Hematology|October 18, 2023
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphomaReid W Merryman, Robert A Redd, Arnold S Freedman, et al.
Cancer|July 28, 2017
C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapyNarendranath Epperla, Kami J Maddocks, Mohammed Salhab, et al.
American Journal of Hematology|November 24, 2016
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapiesLuciano J Costa, Kami Maddocks, Narendranath Epperla, et al.
Cancer Research Communications|January 16, 2023
Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignanciesAndres Chang, Akil Akhtar, Lilin Lai, et al.
Pageof 13